These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 14672944)

  • 1. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis.
    Hosfield DJ; Zhang Y; Dougan DR; Broun A; Tari LW; Swanson RV; Finn J
    J Biol Chem; 2004 Mar; 279(10):8526-9. PubMed ID: 14672944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
    Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa.
    Schmidberger JW; Schnell R; Schneider G
    Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):721-31. PubMed ID: 25760619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.
    Martin MB; Arnold W; Heath HT; Urbina JA; Oldfield E
    Biochem Biophys Res Commun; 1999 Oct; 263(3):754-8. PubMed ID: 10512752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
    Montalvetti A; Bailey BN; Martin MB; Severin GW; Oldfield E; Docampo R
    J Biol Chem; 2001 Sep; 276(36):33930-7. PubMed ID: 11435429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates.
    Cheng F; Oldfield E
    J Med Chem; 2004 Oct; 47(21):5149-58. PubMed ID: 15456258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation.
    Sanchez VM; Crespo A; Gutkind JS; Turjanski AG
    J Phys Chem B; 2006 Sep; 110(36):18052-7. PubMed ID: 16956297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
    Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
    J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
    Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
    J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.
    Tsoumpra MK; Muniz JR; Barnett BL; Kwaasi AA; Pilka ES; Kavanagh KL; Evdokimov A; Walter RL; Von Delft F; Ebetino FH; Oppermann U; Russell RGG; Dunford JE
    Bone; 2015 Dec; 81():478-486. PubMed ID: 26318908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
    Wiemer AJ; Tong H; Swanson KM; Hohl RJ
    Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase.
    Rodriguez JB; Falcone BN; Szajnman SH
    Expert Opin Drug Discov; 2016; 11(3):307-20. PubMed ID: 26781029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
    Dunford JE
    Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate.
    Park J; Lin YS; Tsantrizos YS; Berghuis AM
    Acta Crystallogr F Struct Biol Commun; 2014 Mar; 70(Pt 3):299-304. PubMed ID: 24598914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure.
    Park J; Lin YS; De Schutter JW; Tsantrizos YS; Berghuis AM
    BMC Struct Biol; 2012 Dec; 12():32. PubMed ID: 23234314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010).
    Sun S; McKenna CE
    Expert Opin Ther Pat; 2011 Sep; 21(9):1433-51. PubMed ID: 21702715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.
    Rondeau JM; Bitsch F; Bourgier E; Geiser M; Hemmig R; Kroemer M; Lehmann S; Ramage P; Rieffel S; Strauss A; Green JR; Jahnke W
    ChemMedChem; 2006 Feb; 1(2):267-73. PubMed ID: 16892359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.